Top Markets
Coin of the day
Renascience Inc. Renascience Inc.

Renascience Inc.

4889
Rang in aandelen #21014
Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively... Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached Phase 3 clinical trials for a wide range of indications such as chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets. Another PAI-1 inhibitor, RS5441, is currently in Phase 1 trials for various dermatological conditions. Additionally, RS8001, a water-soluble vitamin, is undergoing Phase 2 clinical development for the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder. Beyond its pharmaceutical ventures, Renascience is also advancing the RS9001 disposable ultrafine endoscope, alongside developing artificial intelligence-driven medical solutions and comprehensive diagnostic tools.
Aandeelprijs
$8.49
Laatst gesynchroniseerd: 2026-08-21
Marktkapitalisatie
$117.03M
Verandering (1 dag)
-4.82%
Verandering (1 jaar)
-45.48%
Land
JP
Handel Renascience Inc. (4889)

Categorie

EPS voor Renascience Inc. (4889)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Renascience Inc. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Renascience Inc. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten
Bedrijf EPS EPS-verschil Land
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH